+

WO2007009529A3 - Composante peptide de calcium - Google Patents

Composante peptide de calcium Download PDF

Info

Publication number
WO2007009529A3
WO2007009529A3 PCT/EP2006/005173 EP2006005173W WO2007009529A3 WO 2007009529 A3 WO2007009529 A3 WO 2007009529A3 EP 2006005173 W EP2006005173 W EP 2006005173W WO 2007009529 A3 WO2007009529 A3 WO 2007009529A3
Authority
WO
WIPO (PCT)
Prior art keywords
calcium
peptide component
caseinophosphopeptide
glycomacropeptide
obtainable
Prior art date
Application number
PCT/EP2006/005173
Other languages
German (de)
English (en)
Other versions
WO2007009529A2 (fr
Inventor
Marco Sell
Dirk Bode
Guenther Sawatzki
Original Assignee
Humana Gmbh
Marco Sell
Dirk Bode
Guenther Sawatzki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humana Gmbh, Marco Sell, Dirk Bode, Guenther Sawatzki filed Critical Humana Gmbh
Priority to EP06754001A priority Critical patent/EP1903895A2/fr
Priority to EA200800205A priority patent/EA016259B1/ru
Publication of WO2007009529A2 publication Critical patent/WO2007009529A2/fr
Publication of WO2007009529A3 publication Critical patent/WO2007009529A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une composante peptide de calcium qui peut être obtenue à partir de: au moins un sel de calcium; un phosphopeptide de caséine et un glycomacropeptide. Il est ainsi possible de se servir du principe du lait selon lequel des quantités importantes du calcium se lient à des protéines.
PCT/EP2006/005173 2005-07-19 2006-05-31 Composante peptide de calcium WO2007009529A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP06754001A EP1903895A2 (fr) 2005-07-19 2006-05-31 Composante peptide de calcium
EA200800205A EA016259B1 (ru) 2005-07-19 2006-05-31 Применение кальций-пептидного компонента для снижения веса тела

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005033630.2 2005-07-19
DE102005033630A DE102005033630A1 (de) 2005-07-19 2005-07-19 Calcium-Peptid-Komponente

Publications (2)

Publication Number Publication Date
WO2007009529A2 WO2007009529A2 (fr) 2007-01-25
WO2007009529A3 true WO2007009529A3 (fr) 2007-06-28

Family

ID=37575596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/005173 WO2007009529A2 (fr) 2005-07-19 2006-05-31 Composante peptide de calcium

Country Status (5)

Country Link
EP (1) EP1903895A2 (fr)
DE (1) DE102005033630A1 (fr)
EA (1) EA016259B1 (fr)
UA (1) UA94716C2 (fr)
WO (1) WO2007009529A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486668B2 (en) 2009-02-24 2013-07-16 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8492124B2 (en) 2009-02-24 2013-07-23 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012536A2 (fr) 2004-07-22 2006-02-02 Ritter Andrew J Procedes et compositions pour le traitement de l'intolerance au lactose
DE102006052560B4 (de) * 2006-11-06 2010-01-21 Humana Milchunion Eg Anti-diabetogene Calcium-Peptid-Zusammensetzung
DE102007022694A1 (de) 2007-05-11 2008-11-13 Humana Milchunion Eg Milchfett-Milchprotein-Zusammensetzung zur Verbesserung der Calcium-Aufnahme
CN103445045A (zh) * 2012-05-30 2013-12-18 孔徐生 一种具有促进钙吸收功能的组合物及其制备方法
CN109805417A (zh) * 2019-03-01 2019-05-28 河南九九一生物科技有限公司 一种能够增加骨密度的保健食品及其加工方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05155774A (ja) * 1991-12-05 1993-06-22 Meiji Milk Prod Co Ltd 月経困難症を緩和する効果のある、 カルシウム利用性に優れた 飲食品及び医薬品
WO2002052954A2 (fr) * 2001-01-08 2002-07-11 Societe Des Produits Nestle S.A. Composition nutritionnelle destinee a une pathologie osseuse
JP2003048843A (ja) * 2002-07-17 2003-02-21 Meiji Milk Prod Co Ltd 月経困難症の予防及び／又は治療用機能性食品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9927603D0 (en) * 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
RU2268069C2 (ru) * 2000-04-18 2006-01-20 Сосьете Де Продюи Нестле С.А. Питательные модули
US6384087B1 (en) * 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
US20030165574A1 (en) * 2002-03-01 2003-09-04 Ward Loren Spencer Compositions and methods for treatment of body weight conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05155774A (ja) * 1991-12-05 1993-06-22 Meiji Milk Prod Co Ltd 月経困難症を緩和する効果のある、 カルシウム利用性に優れた 飲食品及び医薬品
WO2002052954A2 (fr) * 2001-01-08 2002-07-11 Societe Des Produits Nestle S.A. Composition nutritionnelle destinee a une pathologie osseuse
JP2003048843A (ja) * 2002-07-17 2003-02-21 Meiji Milk Prod Co Ltd 月経困難症の予防及び／又は治療用機能性食品

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199329, Derwent World Patents Index; AN 1993-232268, XP002430354 *
DATABASE WPI Week 200344, Derwent World Patents Index; AN 2003-461696, XP002430355 *
KOPRA N ET AL: "EFFECT OF CASEIN PHOSPHOPEPTIDES ON UTILIZATION OF CALCIUM IN VITAMIN D-REPLETE AND VITAMIN D-DEFICIENT RATS", MILCHWISSENSCHAFT, vol. 47, no. 8, 1992, pages 488 - 490, 492, XP009082116, ISSN: 0026-3788 *
SCHÜPBACH P ET AL: "INCORPORATION OF CASEINOGLYCOMACROPEPTIDE AND CASEINOPHOSPHOPEPTIDE INTO THE SALIVARY PELLICLE INHIBITS ADHERENCE OF MUTANS STREPTOCOCCI", JOURNAL OF DENTAL RESEARCH, INTERNATIONAL ASSOCIATION FOR DENTAL RESEARCH, US, vol. 75, no. 10, October 1996 (1996-10-01), pages 1779 - 1788, XP002084521, ISSN: 0022-0345 *
See also references of EP1903895A2 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486668B2 (en) 2009-02-24 2013-07-16 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8492124B2 (en) 2009-02-24 2013-07-23 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8785160B2 (en) 2009-02-24 2014-07-22 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9579340B2 (en) 2009-02-24 2017-02-28 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9592248B2 (en) 2009-02-24 2017-03-14 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use

Also Published As

Publication number Publication date
UA94716C2 (ru) 2011-06-10
EA016259B1 (ru) 2012-03-30
EA200800205A1 (ru) 2008-08-29
EP1903895A2 (fr) 2008-04-02
DE102005033630A1 (de) 2007-01-25
WO2007009529A2 (fr) 2007-01-25

Similar Documents

Publication Publication Date Title
WO2006114439A3 (fr) Nouvelles compositions neutraceutiques
WO2010034718A8 (fr) Proteines recombinantes a activite hemostatique capables d'induire l'agregation plaquettaire
WO2007009529A3 (fr) Composante peptide de calcium
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
WO2007082923A3 (fr) Utilisation de microbilles de proteines dans le domaine cosmetique
WO2009022155A3 (fr) Peptide à formation réduite de dimères
WO2007109456A3 (fr) Biphényle isoxazole sulfonamides substituées en tant que double antagonistes des récepteurs angiotensine et endothéline
WO2008064242A3 (fr) Systèmes de chromatographie comprenant des composants à usage unique
WO2009100270A3 (fr) Tampon dentaire
WO2007092496A3 (fr) 7,9-dihydro-purin-8-one et analogues associés utilisés en tant qu'inhibiteurs de hsp90
WO2011003100A3 (fr) Compositions et procédés de diagnostic et/ou de traitement d'une infection grippale
MY163037A (en) Endoparasiticidal compositions
WO2006099219A3 (fr) Agrafes chirurgicales absorbables
WO2009100278A3 (fr) Boisson comprenant de l'arginine
WO2015075467A3 (fr) Système intestinal modèle
EP2366393A3 (fr) Roflumilast pour le traitement de l'hypertension pulmonaire
WO2010000851A3 (fr) Procédés pour moduler l’angiogenèse via la dystrophine dp71
WO2007053724A3 (fr) Formes cristallines d'un sel de potassium de cefdinir
WO2006099620A3 (fr) Interaction rage/diaphane et compositions et methodes associees
WO2006040574A3 (fr) Proteine lipocaline
WO2006095173A3 (fr) Utilisation d'un compose
WO2007042287A3 (fr) Composes saveur oignon et utilisation de ceux-ci
HK1171027A1 (en) Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof hiv
WO2007062336A3 (fr) Formes de sels
WO2006074341A3 (fr) Nouvelle utilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006754001

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200800205

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2006754001

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载